skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Listed on Nasdaq as AUPH. After market close today,it was halted pending news.Later it announced positive phase 3 trail results showing that its Voclosporin is much better than Standard of Care in Lupus Nephritis.It plans to file NDA submission to FDA in 1st half of 2020,There will be a conference call @ 8.30am ET on Dec 5 .AUPH closed @ US$8.39 up 0.41 on 4.9m shares.However in After Hours trading it was @ US $18.39 to US$19.00 on total 10.6m shares.Thinking of selling my 1.5% position,p/p Can$8.33 especially if the Price is around US$18.39 to 19.00.Should I sell all or partial.Please provide your usual great advices & services.Thanks
Read Answer Asked by Peter on December 05, 2019
Q: Listed as AUPH on Nasdaq. On 9/13,it establishes At-the Market Facility to sell shares up to US$40m from time to time through Jefferies.Since then the price(US$6.59) had dropped sharply to US$3.88(close on Oct 14) Results of Phase 3 on its lead drug expected by year end.My Can $8.33 p/p had dropped 34.7% to a 1% position.Please comment on the company.Also should I buy,hold or sell?Txs for u usual great services & views
Read Answer Asked by Peter on October 16, 2019
Q: Hi 5i,

People on social media (myself included) are trying to understand why there is such a high short position for AUPH, best guess is around 12mm. Also, there is confusion regarding the growing institutional holding of around 45% (best guess), are they taking shares from retail. Further, no one seems to fully understand the implications of the options traded (puts and calls). Can you help clarify, is it possible to read anything into these activities?

Many Thanks,
Read Answer Asked by Mark on May 29, 2017
Q: Hello 5i,

One of my 'fun to own' companies is having both good news and bad news. The CEO just left (bad) and the company is reporting good news on an open trial with just 10 people taking voclosporin, they also have been given fast track designation. The company un-blinds their larger trial (phase 2b) this August. What do you think of all this, is worth holding for the binary event?

Thanks,
Read Answer Asked by Mark on April 26, 2016